Merck's Keytruda Gets Lung Cancer Nod In Europe
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an expanded indication for Merck & Co.’s PD-1 antagonist Keytruda (pembrolizumab).
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an expanded indication for Merck & Co.’s PD-1 antagonist Keytruda (pembrolizumab).